Heterocyclic Compounds

Matches 701 - 750 out of 1,226	< 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 >

Document	Document Title
JP2010515747A	Tetrahydrobiopterin prodrug Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are ...
JP2010513458A	Nicotinamide derivatives as inhibitors of H-PGDS, and their use for the treatment of prostaglandin D2 mediated diseases The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds f...
JP4450869B2	Methods for coloring high molecular weight organic materials and polycyclic pigments PCT No. PCT/EP97/05739 Sec. 371 Date Oct. 5, 1998 Sec. 102(e) Date Oct. 5, 1998 PCT Filed Oct. 17, 1997 PCT Pub. No. WO98/18866 PCT Pub. Date May 7, 1998A process for mass coloring high molecular weight organic material by using a pyrimi...
JP4445667B2	Method for producing 8-methoxy-quinolone carboxylic acid The present invention relates to a novel process for preparing 8-methoxy-3-quinolonecarboxylic acids which are antibiotics having potent antibacterial action.
JP2010508349A	Gypterinyl calcium pentahydrate (DCP) and treatments based on it Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.
JP4423437B2	(6S) -5,6,7,8-Method for producing tetrahydrofolic acid New process for the production of (6S)-5,6,7,8-tetrahydrofolic acid or derivatives thereof starting from the corresponding (6S, 6R) racemic mixture. The procedure comprises in the steps of adding an organic acid to a non-alkaline suspens...
JP2010043094A	NICOTINE IN THERAPEUTIC ANGIOGENESIS AND VASCULOGENESIS To provide methods which can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial diseases by administration of nicotine or other nicotine receptor agonists.The meth...
JP2009298754A	METHOD FOR PRODUCING R-SAPROPTERIN OR SALT THEREOF To provide a production method capable of selectively and industrially advantageously producing R-sapropterin or a salt thereof.There is a method for producing R-sapropterin represented by general formula (2) or a salt thereof comprising...
JP2009274962A	IRON SALEN COMPLEX, MEDICINE HAVING MAGNETISM, GUIDING SYSTEM OF MEDICINE AND DEVICE FOR DETECTING MAGNETISM To achieve a drug delivery system, capable of solving conventional technical problems and easily made as practically useful.An iron salen complex is expressed by formula (1) [wherein, R is a substituent having a hydroxy group]. Since it ...
JP4358521B2	Conjugates and compositions for cell delivery This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin ...
JP4358282B2	Antibodies to OPGL Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount...
JP2009537500A	Dihydropteridine compound as a growth inhibitor Compounds of formula (I), or optionally the pharmacologically acceptable acid addition salts thereof, and their use in the inhibition of PLK activity are described.
JP4330341B2	Cannabinoid receptor ligand There are disclosed compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclose...
JP2009531372A	Pyrimidine, quinazoline, pteridine and triazine derivatives This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions...
JPWO2007119367A1	Compositions containing biopterin and how to use them Tetrahydrobiopterin (BH4), which is used as a pharmaceutical product, is expected to be used and expanded due to its excellent efficacy. However, BH4 is expensive and unstable to oxidation, so it is difficult to apply it for purposes oth...
JP4306825B2	Prophylactic or therapeutic agents for diseases associated with vascular dysfunction associated with insulin resistance It is an object of the present invention to provide a pharmaceutical composition for effectively preventing or improving diseases having vascular dysfunction associated with insulin resistance. The present invention provides pharmaceutic...
JP2009149652A	CONJUGATE AND COMPOSITION FOR CELLULAR DELIVERY To provide a composition and a conjugate for facilitating delivery to a cancer cell.A high-affinity folate receptor is overexpressed in certain cancerous cells. For example, the high-affinity folate receptor is a tumor marker that is ove...
JP2009524672A	Methods and Compositions for Producing High Concentration Aloxazine Solutions Methods are provided for preparation of compositions having an enhanced level of soluble alloxazine, as compared to compositions prepared using conventional techniques. Compositions and a riboflavin form having higher solubility in solut...
JP4287506B2	Use of tetrahydropteridine derivatives as NO-synthase inhibitors The present invention relates to the use of pteridine derivatives of the formula Iin which X is O or NH and R<4>, for example, is hydrogen, phenyl or the radical R<4a>-CH2- and R<4a>, for example, is hydrogen, (C1-C4)-alkylmercapto, the ...
JP2009523740A	(6S)-5,6,7,8-Method for regioselective N (5) -formylation of tetrahydropteroic acid and its derivatives The process according to the invention for regioselective N(5)-formylation of (6S)-5,6,7,8-tetrahydropteroic acid and derivatives thereof which are defined in formula (I) is characterized in that an aqueous buffer solution having a pH of...
JP2009132723A	PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASE ASSOCIATED WITH HYPOFUNCTION OF NOS To provide a therapeutic agent for effectively preventing or ameliorating diseases caused by hypofunction of NOS (NO synthase).The present invention provides a pharmaceutical composition for preventing and/or treating diseases associated...
JP4278384B2	Drugs containing vitamin B2 reducers The present invention provides an agent for preventing or treating infectious diseases, sepsis and/or septic shock, which has an excellent immunostimulating effect. More specifically, it provides an agent for immunostimulation and infect...
JP2009114192A	NEW INHIBITOR FOR FOLIC ACID-DEPENDENT ENZYME To provide a new compound inhibiting enzymes comprising folic acid or a folic acid derivative (folate salt) as an original substrate and usable for treatment of diseases such as cancer.Compounds of formula I, or pharmaceutically acceptab...
JP2009096764A	PIPERIDINE COMPOUND AND ITS USE AS HCV POLYMERASE INHIBITOR To provide a compound having anti-hepatitis C virus (HCV) activity, especially a compound having HCV polymerase inhibition activity.Provided are a compound expressed by general formula [I] (each sign in the formula is separately explaine...
JP2009091358A	PTERIDINE NUCLEOTIDE ANALOG AS FLUORESCENT DNA To provide a new pteridine nucleotide highly fluorescent under physiological condition and usable in the chemical synthesis of fluorescent oligonucleotide.This invention further provides a fluorescent oligonucleotide containing one or at...
JP4250416B2	7-Amino-2-alkylthiopteridine-4-ylamine for the treatment of chemokine-related diseases Pteridine compounds of formula (I) processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases such as psoriasis, rheumatoid arthritis, diseas...
JP2009067695A	CRYSTAL POLYMORPHISM OF BIOPTERIN AND METHOD FOR PRODUCING THE SAME To select and provide a crystalline solid having characteristics of high stability, excellent solid-liquid separability etc., from crystal polymorphism that influences biopterin stability and bioavailability and solid-liquid separability...
JP4241925B2	Method for Producing and Separating Diastereomeric Salt of Holinic Acid A process for the preparation, separation and purification of (6S) and (6R) diastereomers of folinic acid salts with at least dibasic amines is disclosed, which process comprises the hydrolysis of (6RS)-5,10-methenyl-5,6,7,8-tetrahydrofo...
JP2009024011A	CANNABINOID RECEPTOR LIGAND To provide a cannabinoid receptor ligand.A compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of the prodrug, all of which exhibiting anti-inflammatory and immunom...
JP2009501717A	Compositions and Methods for Coupling Multiple Compounds to Scaffold Structures Compositions and methods are provided for coupling a plurality of compounds to a scaffold. Compositions and methods are further provided for catalyzing a reaction between at least one terminal alkyne moiety and at least one azide moiety,...
JP4212470B2	Antibodies to OPGL Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount...
JP2008540486A	Combination with PDE4 inhibitor and tetrahydrobiopterin derivative The invention describes the use of a PDE4 inhibitor in combination with BH4 or a BH4 derivative for the prevention and/or treatment of respiratory diseases.
JP4179879B2	N-substituted non-aryl heterocyclic NMDA / NR2B antagonist Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
JP4174203B2	How to determine susceptibility to bone damage In one aspect, the present invention provides methods for determining susceptibility to bone damage in a subject. In some embodiments, the methods comprise screening for polymorphisms in the MTHFR and collagen Iα1 genes that are associa...
JP4170752B2	Pyrazole compounds useful as protein kinase inhibitors This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridi...
JP2008208138A	ETHYLENEDICYSTEINE (EC)-DRUG CONJUGATE To overcome prior art defects and other defects by providing a new radiolabeling strategy for targeting the tissue for imaging.A radiolabeled tissue-specific ligand, a method for preparing this radiolabeled ligand, a method of using this...
JP2008536862A	High-dose folic acid-containing composition for vascular dysfunction The present invention relates to treatments for hypertension and more particularly, to the use of high dose folic acid in treating dysfunctional conditions associated with vascular function. High dose folic acid can increase vasodilator-...
JP4138870B2	Use of pteridine derivatives as NO-synthase inhibitors PCT No. PCT/EP95/01731 Sec. 371 Date Feb. 18, 1997 Sec. 102(e) Date Feb. 18, 1997 PCT Filed May 6, 1995 PCT Pub. No. WO95/31987 PCT Pub. Date Nov. 30, 1995The present invention relates to the use of pteridine derivatives of the formula I...
JP2008531710A	Regulation of neurodegenerative diseases Methods and compositions are disclosed for selectively interfering with protein synthesis in a central nervous system, meningial, or muscle cell by administrating a pharmacological agent. In particular, methods and compositions that inte...
JP4127851B2	Pyrimidine and guanine derivatives, as well as their use in the treatment of tumor cells The present invention provides certain 6-hetarylalkyloxy pyrimidine derivatives of formula II wherein R is (i) a cyclic group having at least one 5- or 6-membered heterocyclic ring, optionally with a carbocyclic or heterocyclic ring fuse...
JP2008525485A	Positron radiation tomography The invention provides A compound of the formula L-X wherein L is selected from folate, folinic acid, pteropolyglutamic acid, a tetrahydropterin, a dihydrofolate, a tetrahydrofolate, a 1-deaza folate, a 3...
JP2008523090A	Methods and compositions for the treatment of neonatal pulmonary hypertension The present invention is directed to a novel methods and compositions for the therapeutic intervention in persistent pulmonary hypertension of the newborn (PPHN). More specifically, the specification describes methods and compositions fo...
JP4111824B2	Pyrazole compounds useful as protein kinase inhibitors This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridi...
JP2008521774A	Replacement pteridine for the treatment of inflammatory diseases The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous syst...
JP2008521775A	Replacement pteridine for the treatment of inflammatory diseases The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous syst...
JP2008521772A	Replacement pteridine for the treatment of inflammatory diseases Substituted pteridine compounds (I) and their salts are new. Substituted pteridine compounds of formula (I) and their salt are new. R 1heterocyclic ring which contains a nitrogen atom; R 2aryl, het or hetaryl (all optionally substituted ...
JP4105948B2	Pyrazole compounds useful as protein kinase inhibitors This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridi...
JP4105947B2	Triazole compounds useful as protein kinase inhibitors This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridi...
JP4105949B2	Pyrazole compounds useful as protein kinase inhibitors This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridi...
JP2008520574A	Tetrahydrobiopterin Stability Tablet Formulation The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.

Matches 701 - 750 out of 1,226	< 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 >